Ga-NOTA-RF

Phase 1Small molecule

PPeking Union Medical College Hospital

Ga-NOTA-RF is one of 6 small molecule programs targeting Pituitary Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pituitary TumorEnrolling by invitation

Pituitary TumorPhase 1

Enrolling by invitation

Competition

Competitive Landscape

5 competitors in Pituitary Tumor

#DrugCompanyPhaseTrials

Signifor

Opdivo

1 3

Yervoy

Bristol-Myers Squibb

Phase 2

1 4

Avandia

Parlodel

Ga-NOTA-RF

PPeking Union Medical College Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pituitary Tumor1 trial

Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors

Enrolling by invitation·PPeking Union Medical College Hospital·Phase 1·NCT07254104·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ga-NOTA-RF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga-NOTA-RF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga-NOTA-RF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPeking Union Medical College Hospital

Ga-NOTA-RF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pituitary Tumor1 trial

References

Drug Info

Quick Facts

Related News